@davidkzen: A hospital in Guangzhou is organised around longevity and wellness. Not as a department. As the premise. Most of this conversation in the West happens at the level of the individual clinic. But the work that decides what a clinic is able to offer happens above it. China is handling biologics at the national level. Legislation that sets out what doctors are permitted to do. Mandates written into policy rather than left to each practice. That policy reaches the national hospitals first. Then it goes down to the clinics. Then to the individual patient. That order matters more than any single therapy does. Clinical trials there have covered diabetes, Alzheimer's and stroke. Not everyone in the West is comfortable with the pace of it. That disagreement belongs in the picture rather than outside it. There is a second thing that tends to get missed. Traditional Chinese medicine is not being displaced by any of this. It is being integrated into the same clinical setting. Two systems usually described as opposites, working inside one building. Before considering any therapy, ask which regulatory framework governs it where it is offered. And ask a physician who has no financial interest in the answer.
